Patents for Cannabinoids

image

Courtesy of Hemp Solutions:

#1 – “Cannabinoids as Antioxidants and Neuroprotectants”

DESCRIPTION: “Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.”

PUBLICATION NUMBER: US 6630507 B1

FILED BY: The United States Of America As Represented By The Department Of Health And Human Services

LINK: http://www.google.com/patents/US6630507

#2 – “Phytocannabinoids in the treatment of cancer”

DESCRIPTION: “This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.”

“Botanical Drug Substance (BDS)” is Cannabis

PUBLICATION NUMBER: US 20130059018 A1

FILED BY: Otsuka Pharmaceutical Co., Limited, Gw Pharma Limited

LINK: http://www.google.com/patents/US20130059018

#3 – “Treating or preventing diabetes with Cannabidiol (CBD)“

DESCRIPTION: “Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.”

Cannabidiol (CBD) can easily be extracted from high CBD strains of Cannabis such as Hemp varieties grown for Fiber and Food. See Patent #6 – “Cannabinoid Extraction Method” for details on extraction of CBD from Cannabis.

PUBLICATION NUMBER: US 8071641 B2

FILED BY: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Hadsit Hadasit Medical Research Services and Development Ltd.

LINK: https://www.google.com/patents/US8071641?dq=patent+8071641&hl=en&sa=X&ei=GhvsU_fQIY6KyASyzYDICQ&ved=0CB4Q6AEwAA

#4 – “Use of Cannabidiol (CBD) in the treatment of autoimmune hepatitis”

DESCRIPTION: “Methods of treating autoimmune hepatitis are provided. The methods include injecting cannabidiol into the subject, where the cannabidiol is synthetic cannabidiol or natural cannabidiol isolated from other natural cannabinoids.”

PUBLICATION NUMBER: US 8242178 B2

FILED BY: University Of South Carolina

LINK: https://www.google.com/patents/US8242178?dq=patent+8242178&hl=en&sa=X&ei=pBvsU72AIsWUyASc1oGQDg&ved=0CB4Q6AEwAA

#5 – “Cannabinoids used for treating Prostate Cancer”

DESCRIPTION: “Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and/or reducing PSA levels to within the normal range of 0-4.”

PUBLICATION NUMBER: 7597910 B2

FILED BY: Slgm Medical Research Institute

LINK: http://www.google.com/patents/US7597910

#6 – “Cannabinoid extraction method“

DESCRIPTION: A method of extracting cannabinoids, cannflavins, and/or essential oils from hemp and/or of producing a whole hemp extract lacking Δ9-THC is herein described.

PUBLICATION NUMBER: US 6403126 B1

FILED BY: Websar Innovations Inc.

LINK: https://www.google.com/patents/US6403126?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CCUQ6AEwAQ

#7 – “Anti-tumoural effects of cannabinoid combinations“

DESCRIPTION: “The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM)”

PUBLICATION NUMBER: US 8632825 B2

FILED BY: Gw Pharma Limited, Otsuka Pharmaceutical Co., Limited

LINK: https://www.google.com/patents/US8632825?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CDMQ6AEwAw

#8 – “Cannabinoid drugs”

DESCRIPTION: “The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.”

PUBLICATION NUMBER: US 6448288 B1

FILED BY: University Of Massachusetts

LINK: https://www.google.com/patents/US6448288?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CDoQ6AEwBA

#9 – “Cannabinoid receptor antagonists“

DESCRIPTION: “This invention discloses methods of using certain aryl-benzo[b]thiophene and benzo[b]furan compounds to block or inhibit cannabinoid receptors in mammals. It also discloses novel compounds which are antagonists of the cannabinoid receptors and also discloses pharmaceutical formulations which contain the compounds as an active ingredient.”

“Among the many beneficial pharmacological properties attributed to marijuana are: analgesia, lowering blood and intra-ocular pressure, and anti-emetic activity in both mammals and man.”

PUBLICATION NUMBER: US 5596106 A

FILED BY: Eli Lilly And Company

LINK: https://www.google.com/patents/US5596106?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CEEQ6AEwBQ

#10 – “Agonists specific for the peripheral Cannabinoid receptor“

DESCRIPTION: “Among the many beneficial pharmacological properties attributed to marijuana are: analgesia, lowering blood and intra-ocular pressure, and anti-emetic activity in both mammals and man.”

PUBLICATION NUMBER: US 6903137 B2

FILED BY: Yissum Research Development Co. Of The Hebrew University Of Jerusalem

LINK: https://www.google.com/patents/US6903137?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CEgQ6AEwBg

#11 – “Cannabinoid-containing plant extracts as neuroprotective agents“

PUBLICATION NUMBER: EP 1976506 A1

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP1976506A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CE8Q6AEwBw

#12 – “Administration of (natural of synthetic) cannabinoids to (human or non-human) mammals having cerebral tumors, and cannabinoids are chosen from Delta 9- tetrahydrocannabinol, Delta 8-tetrahydrocannabinol, cannabinol and cannabidiol“

PUBLICATION NUMBER: US 20040039048 A1

FILED BY: Manuel Guzman Pastor, Cristina Sanchez Garcia, Ismael Galve Roperh

LINK: https://www.google.com/patents/US20040039048?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CFYQ6AEwCA

#13 – “Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders“

PUBLICATION NUMBER: US 7667053 B2

FILED BY: Merck & Co., Inc.

LINK: https://www.google.com/patents/US7667053?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CF0Q6AEwCQ

#14 – “Comprising regulating the expression or activity of cannabinoid receptors in bone cells“

PUBLICATION NUMBER: US 7749953 B2

FILED BY: Yissum Research Development Company Of The Hebrew University Of Jerusalem

LINK: https://www.google.com/patents/US7749953?dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CBsQ6AEwADgK

#15 – “Medical use for acidic cannabinoids”

PUBLICATION NUMBER: WO 2012144892 A1

FILED BY: Fytagoras B.V.

LINK: https://www.google.com/patents/WO2012144892A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CCIQ6AEwATgK

#16 – “Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment”

PUBLICATION NUMBER: US 6949582 B1

FILED BY: Wallace Walter H

LINK: https://www.google.com/patents/US6949582?dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CCkQ6AEwAjgK

#17 – “Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation“

PUBLICATION NUMBER: WO 2006129178 A1

FILED BY: Glenmark Pharmaceuticals Sa, Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan

LINK: https://www.google.com/patents/WO2006129178A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CDAQ6AEwAzgK

#18 – “Bicyclic cb2 cannabinoid receptor ligands“

PUBLICATION NUMBER: EP 1469842 A2

FILED BY: Pharmos Corporation

LINK: https://www.google.com/patents/EP1469842A2?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CDcQ6AEwBDgK

#19 – “Peripheral cannabinoid receptor (CB2) selective ligands“

PUBLICATION NUMBER: US 6995187 B1

FILED BY: University Of Connecticut

LINK: https://www.google.com/patents/US6995187?dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CD4Q6AEwBTgK

#20 – “Chewing gum compositions comprising cannabinoids“

PUBLICATION NUMBER: US 20110097283 A1

FILED BY: Mareda Holding Bv

LINK: https://www.google.com/patents/US20110097283?dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CEUQ6AEwBjgK

#21 – “Cannabinoid liquid formulations for mucosal administration“

PUBLICATION NUMBER: EP 2314284 A2

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP2314284A2?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CFMQ6AEwCDgK

#22 – “Isolation of herbal and cannabinoid medicinal extracts“

PUBLICATION NUMBER: US 20030017216 A1

FILED BY: Schmidt Robert Gustav, Coco Charles Edward

LINK: https://www.google.com/patents/US20030017216?dq=patent+cannabinoid&hl=en&sa=X&ei=Z1TyU_myGo6VyATtnoKAAg&ved=0CFoQ6AEwCTgK

#23 – “Cannabinoid formulations“

PUBLICATION NUMBER: WO 2013009928 A1

FILED BY: Organic Medical Research

LINK: https://www.google.com/patents/WO2013009928A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CBsQ6AEwADgU

#24 – “Cannabinoid patch and method for cannabis transdermal delivery“

PUBLICATION NUMBER: CA 2356020 C

FILED BY: Lawrence L. Brooke, Cal C. Herrmann, Su Il Yum, Patchtek, Inc.

LINK: https://www.google.com/patents/CA2356020C?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CCIQ6AEwATgU

#25 – “Medicinal acidic cannabinoids“

PUBLICATION NUMBER: EP 1559423 A1

FILED BY: Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno

LINK: https://www.google.com/patents/EP1559423A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CCkQ6AEwAjgU

#26 – “Cannabinoid compositions and methods of use thereof“

PUBLICATION NUMBER: WO 2006024958 A2

FILED BY: Novimmune Sa, Bernard Mach, Francois Mach

LINK: https://www.google.com/patents/WO2006024958A2?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CDcQ6AEwBDgU

#27 – “Cannabinoid crystalline derivatives and process of cannabinoid purification“

PUBLICATION NUMBER: EP 1560819 B1

FILED BY: Mallinckrodt Inc.

LINK: https://www.google.com/patents/EP1560819B1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CD4Q6AEwBTgU

#28 – “Cannabinoid receptor agonists“

PUBLICATION NUMBER: US 5948777 A

FILED BY: Smithkline Beecham Corporation

LINK: https://www.google.com/patents/US5948777?dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CEUQ6AEwBjgU

#29 – “Transmucosal delivery of cannabinoids“

PUBLICATION NUMBER: EP 1539069 A1

FILED BY: University of Mississippi

LINK: https://www.google.com/patents/EP1539069A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=9XHyU4KeBdD9yQSrioCoDw&ved=0CFoQ6AEwCTgU

#30 – “Cannabinoid patch and method for cannabis transdermal delivery“

PUBLICATION NUMBER: US 6328992 B1

FILED BY: Lawrence L. Brooke, Cal C. Herrmann, Su Il Yum

LINK: https://www.google.com/patents/US6328992?dq=patent+cannabinoid&hl=en&sa=X&ei=JnryU9-nCcu3yATYloGQBQ&ved=0CDAQ6AEwAzge

#31 – “Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases“

PUBLICATION NUMBER: WO 2001058869 A2

FILED BY: Chen Bang Chi, Ping Chen, John Hynes Jr, Peter Kiener, Katerina Leftheris, Malinda Longphre, Derek J Norris, Chennagiri R Pandit, Steven Spergel, Squibb Bristol Myers Co, John Tokarski, Stephen Wrobleski, Hong Wu, Rulin Zhao

LINK: https://www.google.com/patents/WO2001058869A2?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=JnryU9-nCcu3yATYloGQBQ&ved=0CEUQ6AEwBjge

#32 – “Anti-tumoural effects of cannabinoid combinations”

PUBLICATION NUMBER: EP 2318000 A1

FILED BY: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.

LINK: https://www.google.com/patents/EP2318000A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=JnryU9-nCcu3yATYloGQBQ&ved=0CEwQ6AEwBzge

#33 – “Use of cannabinoids as anti-inflammatory agents“

PUBLICATION NUMBER: US 6410588 B1

FILED BY: The Mathilda And Terence Kennedy Institute Of Rheumatology, Yissum Research And Development Company Of The Hebrew University Of Jerusalem

LINK: https://www.google.com/patents/US6410588?dq=patent+cannabinoid&hl=en&sa=X&ei=JnryU9-nCcu3yATYloGQBQ&ved=0CFMQ6AEwCDge

#34 – “Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy“

PUBLICATION NUMBER: CA 2322549 A1

FILED BY: A. Paul Hornby, Martin D. Sutherland, Pavel U. Dimotoff

LINK: https://www.google.com/patents/CA2322549A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=JnryU9-nCcu3yATYloGQBQ&ved=0CFoQ6AEwCTge

#35 – “New use for cannabinoid (CBD)”

PUBLICATION NUMBER: WO 2007138322 A1

FILED BY: Gw Pharma Ltd, Geoffrey Guy, Roger Pertwee, Adele Thomas

LINK: https://www.google.com/patents/WO2007138322A1?cl=en&dq=patent+cannabinoid&hl=en&sa=X&ei=e33yU6aYJof4yQS3xILYDw&ved=0CD4Q6AEwBTgo

#36 – “Liquid cannabinoid formulations”

PUBLICATION NUMBER: US 8222292 B2

FILED BY: Insys Therapeutics, Inc.

LINK: https://www.google.com/patents/US8222292?dq=patent+cannabinoid&hl=en&sa=X&ei=e33yU6aYJof4yQS3xILYDw&ved=0CEUQ6AEwBjgo

#37 – “Cannabinoid derivatives, methods of making, and use thereof“

PUBLICATION NUMBER: US 7169942 B2

FILED BY: University Of Tennessee Research Foundation

LINK: https://www.google.com/patents/US7169942?dq=patent+cannabinoid&hl=en&sa=X&ei=e33yU6aYJof4yQS3xILYDw&ved=0CFMQ6AEwCDgo

#38 – “Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same“

DESCRIPTION: “Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.”

“The clinical usefulness of the cannabinoids, including cannabidiol (“CBD”), to provide analgesia and neuroprotection, reduce inflammation, help alleviate nausea and emesis, as well as treat epilepsy, anxiety disorders, and glaucoma, has been well-recognized. In addition, it is also well-known that cannabidiol lacks the psychoactive effects seen in many of the other cannabinoids, including Δ9-tetrahydrocannabinol, which is currently available in an oral dosage, sold under the trade name Marinol®.”

PUBLICATION NUMBER: US 8293786 B2

FILED BY: Alltranz Inc.

LINK: https://www.google.com/patents/US8293786?dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CCUQ6AEwAQ

#39 – “Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy“

DESCRIPTION: “The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels,for use in the treatment of epilepsy.The SAED is preferably one which • modifies low-threshold or transient neuronal calcium currents,or • reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.”

PUBLICATION NUMBER: WO 2012093255 A1

FILED BY: Gw Pharma Limited, Otsuka Pharmaceutical Co. Limited

LINK: https://www.google.com/patents/WO2012093255A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CDoQ6AEwBA

#40 – “Method of preparing cannabidiol (CBD) from plant material“

DESCRIPTION: “The invention relates to methods of preparing cannabidiol in substantially pure form starting from plant material. Also described are substantially pure preparations of cannabidiol having a chromatographic purity of 95% or greater.”

PUBLICATION NUMBER: EP 1542952 A1

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP1542952A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CEEQ6AEwBQ

#41 – “Converting cannabidiol to Delta 8 or Delta 9-tetrahydrocannabinol by mixing the diol with a catalyst and solvent and allowing the mixture to separate, removing the organic phase; and eluting the tetrahydrocannabinol from the organic phase“

DESCRIPTION: “Methods of converting cannabidiol to Δ8-tetrahydrocannabinol or Δ9-tetrahydrocannabinol are described. The described methods produce higher yields and higher purity compared to prior art methods.”

PUBLICATION NUMBER: US 7399872 B2

FILED BY: Webster G R Barrie, Sarna Leonard P, Raphael Mechoulam

LINK: https://www.google.com/patents/US7399872?dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CEgQ6AEwBg

#42 – “Novel cannabidiol derivatives and their use as anti-inflammatory agents“

DESCRIPTION: “NOVEL CANNABIDIOL DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS”

PUBLICATION NUMBER: WO 2008107879 A1

FILED BY: Yissum Res Dev Co, Raphael Mechoulam, Natalya Kogan, Ruth Gallily, Aviva Breuer

LINK: https://www.google.com/patents/WO2008107879A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CFYQ6AEwCA

#43 – “Use of cannabidiol for the inhibition of brain tumour cell migration“

DESCRIPTION: “The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.”

PUBLICATION NUMBER: EP 1802274 B1

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP1802274B1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=uaTzU8rRCcayyASflYCYCA&ved=0CF0Q6AEwCQ

#44 – “Supercritical co2 extraction of tetrahydrocannabinol and cannabidiol from cannabis plant material“

DESCRIPTION: “The invention relates to a method for producing an extract from cannabis plant matter, containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof. According to said method, the dried plant matter is ground and subjected to a CO2 extraction and the primary extract obtained is separated. The inventive method permits .DELTA.8 or .DELTA.9 tetrahydrocannabinol to be selectively obtained both from industrial hemp and from drug-producing hemp, optionally after dissolving the primary extract in ethanol, separating undesirable waxes and removing the solvent under reduced pressure. ”

PUBLICATION NUMBER: CA 2424356 A1

FILED BY: Delta-9-Pharma Gmbh, Adam Muller

LINK: https://www.google.com/patents/CA2424356A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=q6_zU9umCZOXyASJpYGAAQ&ved=0CCIQ6AEwATgK

#45 – “Use of cannabidiol prodrugs in topical and transdermal administration with microneedles“

DESCRIPTION: “Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.”

PUBLICATION NUMBER: EP 2473475 A1

FILED BY: AllTranz Inc.

LINK: https://www.google.com/patents/EP2473475A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=q6_zU9umCZOXyASJpYGAAQ&ved=0CCkQ6AEwAj

#46 – “Pharmaceutical compositions comprising cannabidiol derivatives“

DESCRIPTION: “The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives.It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.”

PUBLICATION NUMBER: WO 2001095899 A2

FILED BY: Breuer Aviva, Fride Ester, Gallily Ruth, Hanus Lumir, Mechoulam Raphael, Tchilibon Susana, Yissum Res Dev Co

LINK: https://www.google.com/patents/WO2001095899A2?cl=en&dq=cannabidiol&hl=en&sa=X&ei=q6_zU9umCZOXyASJpYGAAQ&ved=0CEwQ6AEwBzgK

#47 – “Therapeutic uses of cannabidiol compounds“

DESCRIPTION: “This invention relates to the use of cannabidiol compounds in therapy.”

“Use of a cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b), the fundamental parameter being selected from at least one of (i) dimension of heart scars; (ii) blood/plasma levels; (iii) atherosclerosis.”

PUBLICATION NUMBER: EP 2007376 B1

FILED BY: Hadasit Medical Research Services And Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem

LINK: https://www.google.com/patents/EP2007376B1?cl=en&dq=cannabidiol&ei=q6_zU9umCZOXyASJpYGAAQ

#48 – “Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts“

DESCRIPTION: “The invention relates to a method for producing an extract from cannabis plant matter, containing tetrahydrocannabinol, cannabidiol and optionally the carboxylic acids thereof. According to said method, the dried plant matter is ground and subjected to a CO2 extraction and the primary extract obtained is separated. The invention method permits Δ8 or Δ9 tetrahydrocannabinol to be selectively obtained both from industrial hemp and from drug-producing hemp, optionally after dissolving the primary extract in ethanol, separating undesirable waxes and removing the solvent under reduced pressure. ”

PUBLICATION NUMBER: US 20040049059 A1

FILED BY: Adam Mueller

LINK: https://www.google.com/patents/US20040049059?dq=cannabidiol&hl=en&sa=X&ei=78XzU_eUFOroigK-_ID4Ag&ved=0CBsQ6AEwADgU

#49 – “Anti-nausea and anti-vomiting activity of cannabidiol compounds“

DESCRIPTION: “The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.”

PUBLICATION NUMBER: US 8119697 B2

FILED BY: Yissum Research Development Company Of The Hebrew University Of Jerusalem

LINK: https://www.google.com/patents/US8119697?dq=cannabidiol&hl=en&sa=X&ei=78XzU_eUFOroigK-_ID4Ag&ved=0CCIQ6AEwATgU

#50 – “Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives“

DESCRIPTION: “Cannabinoid derivatives are known for their functions in the central as well as peripheral nervous system. The present invention describes some novel (+)-cannabidiol (CBD) derivatives, and their selective activity in the peripheral and not in the central nervous system. Thus, it is an object of the invention to provide the use of (+)-CBD derivatives as analgesics, anti-inflammatory and anti-diarrheal agents.”

PUBLICATION NUMBER: WO 2005023741 A3

FILED BY: Ariel Ltd, Fride Ester, Mechoulam Raphael, Yissum Res Dev Co

LINK: https://www.google.com/patents/WO2005023741A3?cl=en&dq=cannabidiol&hl=en&sa=X&ei=78XzU_eUFOroigK-_ID4Ag&ved=0CCkQ6AEwAjgU

#51 – “Use of cannabidiol in the treatment of chemotherapy-induced nausea and vomiting“

DESCRIPTION: “Cannabidiol for use in the treatment of chemotherapy-induced nausea.”

PUBLICATION NUMBER: EP 1476145 B1

FILED BY: Yissum Research Development Company Of The Hebrew University Of Jerusalem

LINK: https://www.google.com/patents/EP1476145B1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=gf_zU4qEM8SXyASyvoGgBQ&ved=0CEwQ6AEwBzgU

#52 – “New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabidivarin“

DESCRIPTION: “Treating or preventing diabetes with cannabidiol (CBD)”

PUBLICATION NUMBER: EP 2173332 A1

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP2173332A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=EQD0U4fDDs_5yQS1-4Eo&ved=0CCIQ6AEwATge

#53 – “Use of Cannabidiol in the Treatment of Hepatitis“

DESCRIPTION: “Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune systems mediating a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. Cannabidiol (CBD) is the most abundant nonpsychotropic plant cannabinoid but has not been studied as extensively as Δ9-tetrahydrocannabinol (THC). The present disclosure reports the immunosuppressive properties of CBD and demonstrates that CBD induces apoptosis in thymocytes and splenocytes and inhibits the proliferative responsiveness of T and B cells. This indicates that CB2 selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents.”

PUBLICATION NUMBER: US 20120302646 A1

FILED BY: University Of South Carolina

LINK: https://www.google.com/patents/US20120302646?dq=cannabidiol&hl=en&sa=X&ei=EQD0U4fDDs_5yQS1-4Eo&ved=0CDAQ6AEwAzge

#54 – “Process for the production of dronabinol“

DESCRIPTION: “A method for the production of dronabinol is disclosed, whereby: a) cannabidiol is isolated from fibrous hemp as cannabidiol acid, b) the cannabidiol, optionally obtained by decarboxylation, is cyclised in the presence of Lewis acids in a non-polar solvent to give dronabinol, c) the above is isolated by a chromatographic method and d) the residue obtained from the eluant after distilling off the solvent is purified by vacuum distillation. The dronabinol can be used for dispensing purposes in a syringe filled therewith and as inhalation solution for thermal nebulisation with hot air.”

PUBLICATION NUMBER: US 8242178 B2

FILED BY: University Of South Carolina

LINK: https://www.google.com/patents/US8242178?dq=patent+8242178&hl=en&sa=X&ei=pBvsU72AIsWUyASc1oGQDg&ved=0CB4Q6AEwAA

#55 – “Cannabinoids used for treating Prostate Cancer”

DESCRIPTION: “Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and/or reducing PSA levels to within the normal range of 0-4.”

PUBLICATION NUMBER: 7597910 B2

FILED BY: Slgm Medical Research Institute

LINK: http://www.google.com/patents/US7597910

#56 – “Cannabinoid extraction method“

DESCRIPTION: A method of extracting cannabinoids, cannflavins, and/or essential oils from hemp and/or of producing a whole hemp extract lacking Δ9-THC is herein described.

PUBLICATION NUMBER: US 6403126 B1

FILED BY: Websar Innovations Inc.

LINK: https://www.google.com/patents/US6403126?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CCUQ6AEwAQ

#57 – “Anti-tumoural effects of cannabinoid combinations“

DESCRIPTION: “The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM)”

PUBLICATION NUMBER: US 8632825 B2

FILED BY: Gw Pharma Limited, Otsuka Pharmaceutical Co., Limited

LINK: https://www.google.com/patents/US8632825?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CDMQ6AEwAw

#58 – “Cannabinoid drugs”

DESCRIPTION: “The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.”

PUBLICATION NUMBER: US 6448288 B1

FILED BY: University Of Massachusetts

LINK: https://www.google.com/patents/US6448288?dq=patent+cannabinoid&hl=en&sa=X&ei=M1DyU6KwDYHcOuy6gLgF&ved=0CDoQ6AEwBA

#59 – “Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease“

DESCRIPTION: “The present invention relates to the use of a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of an inflammatory bowel disease, wherein the ratio of THC to CBD (w/w) is 2:1 to 1:2, and wherein the CBD is in a unit dose form suitable for delivering a daily dose of CBD in the dose range of from between 5 to 200mg.

PUBLICATION NUMBER: EP 2182940 B1

FILED BY: GW Pharma Limited

LINK: https://www.google.com/patents/EP2182940B1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=bQH0U9PrJsr-yQScqoH4DA&ved=0CDAQ6AEwAzgo

#60 – “Synergistic therapies of cannabidiol with hypothermia for neuroprotection“

DESCRIPTION: “The present invention relates to the combination of the phytocannabinoid cannabidiol with therapeutic hypothermia for use in the treatment of neuroprotection or astroprotection.”

PUBLICATION NUMBER: WO 2013182862 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/WO2013182862A1?cl=en&dq=cannabidiol&hl=en&sa=X&ei=bQH0U9PrJsr-yQScqoH4DA&ved=0CD4Q6AEwBTgo

#61 – “Therapeutic uses of Cannabigerol (CBG)“

DESCRIPTION: “The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn’s disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.”

PUBLICATION NUMBER: EP 2175848 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/EP2175848A1?cl=en&dq=cannabigerol&hl=en&sa=X&ei=BAT0U9XXKNixyAT40IL4AQ&ved=0CB4Q6AEwAA

#62 – “Cannabinoids for use in the treatment of neuropathic pain“

DESCRIPTION: “The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.”

PUBLICATION NUMBER: EP 2709604 A1

FILED BY: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.

LINK: https://www.google.com/patents/EP2709604A1?cl=en&dq=cannabigerol&hl=en&sa=X&ei=BAT0U9XXKNixyAT40IL4AQ&ved=0CFYQ6AEwCA

#63 – “Cannabis sativa plants rich in cannabichromene (CBC) and its acid, extracts thereof and methods of obtaining extracts therefrom“

DESCRIPTION: “The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a botanical drug substance (BDS) and a purified BDS; • A formulation comprising the BRM, BDS, purified BDS or other extract; • The use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; • A method of deriving plants yielding a high proportion of the cannabinoid CBC (A) at the expense of other cannabinoids; • A method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and • A method of extracting CBC(A) from said plants.”

PUBLICATION NUMBER: US 20110098348 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/US20110098348?dq=cannabichromene&hl=en&sa=X&ei=NrYDVLHMDILNggTh8IKwDg&ved=0CB8Q6AEwAA

#64 – “Pharmaceutical compositions comprising cannabichromene type compounds“

DESCRIPTION: “The invention relates to the use of cannabichromene type compounds and derivatives thereof in the treatment of mood disorders.”

PUBLICATION NUMBER: US 8470874 B2

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/US8470874?dq=cannabichromene&hl=en&sa=X&ei=NrYDVLHMDILNggTh8IKwDg&ved=0CCYQ6AEwAQ

#65 – “Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV.“

DESCRIPTION: “The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.”

PUBLICATION NUMBER: US 6541510 B2

FILED BY: Immugen Pharmaceuticals, Inc.

LINK: https://www.google.com/patents/US6541510?dq=cannabichromene&hl=en&sa=X&ei=NrYDVLHMDILNggTh8IKwDg&ved=0CDQQ6AEwAw

#66 – “Phytocannabinoids for use in the treatment of intestinal inflammatory diseases“

DESCRIPTION: “The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn’s disease.”

PUBLICATION NUMBER: WO 2013076487 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/WO2013076487A1?cl=en&dq=cannabichromene&hl=en&sa=X&ei=NrYDVLHMDILNggTh8IKwDg&ved=0CEQQ6AEwBQ

#67 – “Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells“

DESCRIPTION: “The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.”

PUBLICATION NUMBER: WO 2013076471 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/WO2013076471A1?cl=en&dq=tetrahydrocannabivarin&hl=en&sa=X&ei=wbkDVJirB9DJggTZn4CwCg&ved=0CB8Q6AEwAA

#68 – “THCV and THCV extracts derived from plant material“

DESCRIPTION: “The invention relates to TIICV and THCV containing extracts derived from plant material. A botanical drug substance preferably comprises at least 70% THCV and the isolated THCV is preferably 95% THCV. Most preferably it is in a crystalline form. ”

PUBLICATION NUMBER: EP 2161262 A1

FILED BY: Gw Pharma Limited

LINK: https://www.google.com/patents/EP2161262A1?cl=en&dq=tetrahydrocannabivarin&hl=en&sa=X&ei=wbkDVJirB9DJggTZn4CwCg&ved=0CF4Q6AEwCQ

Advertisements

2 thoughts on “Patents for Cannabinoids

    • IMO how can they outlaw a plant that is grown from the earth, one that cures so many ailments and produces so many products sustainably and then patent the compounds produced by said plant. This is corruption, although acceptable now, it won’t be in the future.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s